Nimbus Therapeutics

Nimbus Therapeutics is committed to applying highly advanced computational technologies to the design and development of novel therapeutic approaches, primarily focusing on diseases driven by overlapping biological mechanisms, such as metabolic disorders, oncology, and immunology. The company’s main projects currently under development include: the small molecule Tyk2 inhibitor and STING antagonist in collaboration with Celgene, as well as the STING agonist exclusively owned by Nimbus.